The term “sarcomas” encompasses more than 50 different malignancies with differing molecular biology, clinical behaviour, responsiveness to treatment, and prognosis, and there is no current evidence that inhibition of the mTOR pathway is an active therapeutic strategy in low grade ESS. This evidence concerns the gene MTOR and endometrioid stromal sarcoma.